{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:02Z","timestamp":1793896082920,"version":"4.8.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Phosphoinositide-3-kinase \u03b4 (PI3K\u03b4) is found in immune cells and is part of the PI3K\/AKT\/mTOR\/S6K signalling pathway essential to cell survival, growth and differentiation. Hyperactivation of PI3K\u03b4 enzyme results in Activated PI3-kinase delta syndrome (APDS). This childhood onset, autosomal dominant, combined immunodeficiency, is caused by heterozygous gain of function (GOF) mutations in <jats:italic>PIK3CD<\/jats:italic> (encodes PI3K\u03b4 catalytic subunit p110\u03b4), mutations in <jats:italic>PIK3R1<\/jats:italic> (encodes PI3K\u03b4 regulatory subunit p85\u03b1) or LOF mutations in <jats:italic>PTEN<\/jats:italic> (terminates PI3K\u03b4 signalling) leading to APDS1, APDS2 and APDS-Like (APDS-L), respectively. APDS was initially described in 2013 and over 285 cases have now been reported. Prompt diagnosis of APDS is beneficial as targeted pharmacological therapies such as sirolimus and potentially PI3K\u03b4 inhibitors can be administered. In this review, we provide an update on the clinical and laboratory features of this primary immunodeficiency. We discuss the common manifestations such as sinopulmonary infections, bronchiectasis, lymphoproliferation, susceptibility to herpesvirus, malignancy, as well as more rare non-immune features such as short stature and neurodevelopmental abnormalities. Laboratory characteristics, such as antibody deficiency and B cell and T cell, phenotypes are also summarised.<\/jats:p>","DOI":"10.3389\/fped.2021.702872","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:22:50Z","timestamp":1628144570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Disorders Related to PI3K\u03b4 Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes"],"prefix":"10.3389","volume":"9","author":[{"given":"Vyanka","family":"Redenbaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.jbior.2019.100657","article-title":"Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease","volume":"75","author":"Rathinaswamy","year":"2020","journal-title":"Adv Biol Regul."},{"key":"B5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ng0497-356","article-title":"Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23","volume":"15","author":"Steck","year":"1997","journal-title":"Nat Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","volume":"143","author":"Nunes-Santos","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2016.03.059","article-title":"Immune dysregulation in patients with PTEN hamartoma tumor syndrome: analysis of FOXP3 regulatory T cells","volume":"139","author":"Chen","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.jaci.2016.07.010","article-title":"Increased PI3K\/Akt activity and deregulated humoral immune response in human PTEN deficiency","volume":"138","author":"Driessen","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmedgenet-2015-103266","article-title":"Cowden's syndrome with immunodeficiency","volume":"52","author":"Browning","year":"2015","journal-title":"J Med Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jaci.2016.03.055","article-title":"Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase \u03b4 syndrome-like immunodeficiency","volume":"138","author":"Tsujita","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3389\/fimmu.2018.00568","article-title":"Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3K\u03b4 syndrome","volume":"9","author":"Asano","year":"2018","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0960-9822(07)00488-5","article-title":"High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice","volume":"8","author":"Suzuki","year":"1998","journal-title":"Curr Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","article-title":"Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review","volume":"59","author":"Jamee","year":"2020","journal-title":"Clin Rev Allergy Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science."},{"key":"B17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u03b4 syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase \u03b4 syndrome: the european society for immunodeficiencies-activated phosphoinositide 3-kinase \u03b4 syndrome registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s10875-018-0568-x","article-title":"Report of a chinese cohort with activated phosphoinositide 3-kinase \u03b4 syndrome","volume":"38","author":"Wang","year":"2018","journal-title":"J Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","article-title":"Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase \u03b4 syndrome type 1","volume":"143","author":"Okano","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1863982","article-title":"The first iranian cohort of pediatric patients with activated phosphoinositide 3-kinase-\u03b4 (PI3K\u03b4) syndrome (APDS)","author":"Fekrvand","year":"2021","journal-title":"Immunol Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fimmu.2018.00338","article-title":"Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome","volume":"9","author":"Condliffe","year":"2018","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3349\/ymj.2020.61.6.542","article-title":"Successful sirolimus treatment for korean patients with activated phosphoinositide 3-kinase \u03b4 syndrome 1: the first case series in Korea","volume":"61","author":"Kang","year":"2020","journal-title":"Yonsei Med J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.immuni.2006.08.015","article-title":"Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling","volume":"25","author":"Omori","year":"2006","journal-title":"Immunity."},{"key":"B26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fimmu.2018.00237","article-title":"Herpesviruses in the activated phosphatidylinositol-3-kinase-\u03b4 syndrome","volume":"9","author":"Cohen","year":"2018","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1053\/j.gastro.2012.01.011","article-title":"Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome","volume":"142","author":"Heindl","year":"2012","journal-title":"Gastroenterology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.tranon.2018.11.003","article-title":"PTEN hamartoma tumor syndrome and immune dysregulation","volume":"12","author":"Eissing","year":"2019","journal-title":"Transl Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","article-title":"Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility","volume":"34","author":"Crank","year":"2014","journal-title":"J Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2017.01.004","article-title":"Genetic defects in PI3K\u03b4 affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections","volume":"176","author":"Wentink","year":"2017","journal-title":"Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jaip.2018.01.005","article-title":"Liver disturbances in activated phosphoinositide 3-kinase \u03b4 syndrome","volume":"6","author":"Ben-Yakov","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10875-014-0109-1","article-title":"Gain of function mutations of PIK3CD as a cause of primary sclerosing cholangitis","volume":"35","author":"Hartman","year":"2015","journal-title":"J Clin Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1371\/journal.pone.0000869","article-title":"Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase","volume":"2","author":"Eickholt","year":"2007","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/pai.12585","article-title":"Activated PI3K\u03b4 syndrome type 2: two patients, a novel mutation, and review of the literature","volume":"27","author":"Olbrich","year":"2016","journal-title":"Pediatr Allergy Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/jnci\/djt277","article-title":"Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria","volume":"105","author":"Pilarski","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"B37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ajhg.2013.06.005","article-title":"Mutations in PIK3R1 cause SHORT syndrome","volume":"93","author":"Dyment","year":"2013","journal-title":"Am J Hum Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3K\u03b4 syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.079","article-title":"International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome","author":"Dimitrova","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d-targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.702872\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T06:22:52Z","timestamp":1628144572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.702872\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":40,"alternative-id":["10.3389\/fped.2021.702872"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.702872","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"article-number":"702872"}}